Global drugmakers slam latest Russian initiatives on drug procurement

6 December 2016

Global drugmakers operating their plants in Russia have criticized the latest state initiative to introduce new restrictions on the participation of foreign drug manufacturers in tenders for the public procurement of drugs for state needs, reports The Pharma Letter’s local correspondent.

According to producers, the provision of an absolute advantage to Russian companies which use domestically-made substances in their production during state tenders for the public procurement of drugs are totally unfair. Producers believe that the latest state initiative does not comply with global trends of protectionism policies and can lead to a significant increase in prices for drugs during these tenders.

In addition, according to the foreign firms, the new proposal creates additional obstacles for pharmaceutical companies. Given the volume of the Russian market, the cost of the production and the purchase price of a drug manufactured on full cycle basis will be higher than the purchase of a substance from a specialized chain of international manufacturers.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK